Chronic obstructive pulmonary disease and COVID-19: topical issues
https://doi.org/10.18093/0869-0189-2020-30-5-599-608
Abstract
The problem of comorbidity of new coronaviral infection (COVID-19) and chronic obstructive pulmonary disease (COPD) is acute, considering similarity of clinical manifestations, diagnostic difficulties, the potential severe disease course. Patients with COPD represent a vulnerable group of infected SARS-CoV-2, with a complicated disease course and frequent adverse outcome. Features of the spread of the virus limit treatment and diagnosis for patients with COPD, making it difficult to provide medical care during the pandemic. The negative results of some clinical studies of antiviral drugs for patients with COVID-19 indicate the need for a search for new drugs; for this reason, analysis of the anti-inflammatory effect on the lungs in infection COVID-19 of drugs of basic COPD therapy is promising.
About the Authors
A. M. Shchikota
Moscow Centre for Research and Practice in Medical Rehabilitation, Restorative and Sports Medicine
Russian Federation
Russian Federation
Aleksey M. Shchikota – Candidate of Medicine, Leading Researcher
Zemlyanoy Val 53, Moscow, 105120
tel.: (916) 544-96-27
I. V. Pogonchenkova
Moscow Centre for Research and Practice in Medical Rehabilitation, Restorative and Sports Medicine
Russian Federation
Russian Federation
Irena V. Pogonchenkova – Doctor of Medicine, Director
Zemlyanoy Val 53, Moscow, 105120
tel.: (495) 917-11-64
E. A. Turova
Moscow Centre for Research and Practice in Medical Rehabilitation, Restorative and Sports Medicine
Russian Federation
Russian Federation
Elena A. Turova – Doctor of Medicine, Deputy Director on Scientific Research
Zemlyanoy Val 53, Moscow, 105120
tel.: (495) 616-81-06
M. A. Rassulova
Moscow Centre for Research and Practice in Medical Rehabilitation, Restorative and Sports Medicine
Russian Federation
Russian Federation
Marina A. Rassulova – Doctor of Medicine, First deputy Director
Zemlyanoy Val 53, Moscow, 105120
tel.: (495) 916-45-62
S. A. Gumenyuk
Scientific Center of Emergency of Moscow Healthcare Department
Russian Federation
Russian Federation
Sergey A. Gumenyuk – Candidate of Medicine, Deputy Director for Medical Work
Bol’shaya Sukharevskaya pl. 5/1, Moscow, 129090
tel.: (495) 608-75-55
References
1. Pogonchenkova I.V., Zadionchenko V.S. [Pulmonogenic hypertension and systemic inflammation]. Kardiologiya. 2012; (6): 51 (in Russian).
2. Leung J.M., Yang C.X., Tam A. et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur. Respir. J. 2020; 55 (5): 2000688. DOI: 10.1183/13993003.00688-2020.
3. Russo P., Bonassi S., Giacconi R. et al. COVID-19 and smoking: is nicotine the hidden link? Eur. Respir. J. 2020; 55 (6): 2001116. DOI: 10.1183/13993003.01116-2020.
4. Leung J.M., Yang C.X., Sin D.D. COVID-19 and nicotine as a mediator of ACE-2. Eur. Respir. J. 2020; 55 (6): 2001261. DOI: 10.1183/13993003.01261-2020.
5. Saheb Sharif-Askari N., Saheb Sharif-Askari F., Alabed M. et al. Airways expression of SARS-CoV-2 receptor, АПФ-2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD. Version 2. Mol. Ther. Methods Clin. Dev. 2020; 18: 1–6. DOI: 10.1016/j.omtm.2020.05.013.
6. Zhang J.J., Dong X., Cao Y.Y. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020; 75 (7): 1730–1741. DOI: 10.1111/all.14238.
7. Guan W.J., Ni Z.Y., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020; 382 (18): 1708–1720. DOI: 10.1056/NEJMoa2002032.
8. Emami A., Javanmardi F., Pirbonyeh N., Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch. Acad. Emerg. Med. 2020; 8 (1): e35.
9. Goyal P., Choi J.J., Pinheiro L.C. et al. Clinical characteristics of COVID-19 in New York city: Multicenter study. N. Engl. J. Med. 2020; 382 (24): 2372–2374. DOI: 10.1056/NEJMc2010419.
10. Rossato M., Russo L., Mazzocut S. et al. Current smoking is not associated with COVID-19. Eur. Respir. J. 2020; 55 (6): 2001290. DOI: 10.1183/13993003.01290-2020.
11. Lupia T., Scabini S., Mornese Pinna S. et al. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. J. Glob. Antimicrob. Resist. 2020; 21: 22–27. DOI: 10.1016/j.jgar.2020.02.021.
12. Lian J., Jin X., Hao S. et al. Analysis of epidemiological and clinical features in older patients with corona virus disease 2019 (COVID-19) out of Wuhan. Clin. Infect. Dis. 2020; 71 (15): 740–747. DOI: 10.1093/cid/ciaa242.
13. Polverino F. Cigarette smoking and COVID-19: A complex interaction. Am. J. Respir. Crit. Care Med. 2020; 202 (3): 471–472. DOI: 10.1164/rccm.202005-1646LE.
14. Farsalinos K., Angelopoulou A., Alexandris N., Poulas K. COVID-19 and the nicotinic cholinergic system. Eur. Respir. J. 2020; 56 (1): 2001589. DOI: 10.1183/13993003.01589-2020.
15. Leung J.M., Yang C.X., Sin D.D. Reply to: “Current smoking is not associated with COVID-19”. Eur. Respir. J. 2020; 55 (6): 2001340. DOI: 10.1183/13993003.01340-2020.
16. Lippi G., Henry B.M. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir. Med. 2020; 167: 105941. DOI: 10.1016/j.rmed.2020.105941.
17. Wang B., Li R., Lu Z., Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020; 12 (7): 6049–6057. DOI: 10.18632/aging.103000.
18. Guan W.J., Liang W.H., Zhao Y. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur. Respir. J. 2020; 55 (5): 2000547. DOI: 10.1183/13993003.00547-2020.
19. Jain V., Yuan J.M. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int. J. Public. Health. 2020; 65 (5): 533–546. DOI: 10.1007/s00038-02001390-7.
20. Somani S., Richter F., Fuster V. et al. Characterization of patients who return to hospital following discharge from hospitalization for COVID-19. medRxiv [Preprint. Posted: 2020, May 22]. DOI: 10.1101/2020.05.17.20104604.
21. Shi S., Qin M., Cai Y. et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur. Heart. J. 2020; 41 (22): 20702079. DOI: 10.1093/eurheartj/ehaa408.
22. Parohan M., Yaghoubi S., Seraji A. et al. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020, Jun. 8. DOI: 10.1080/13685538.2020.1774748.
23. Zhao Q., Meng M., Kumar R. et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J. Med. Virol. 2020; 92 (10): 1915–1921. DOI: 10.1002/jmv.25889.
24. Guan W.J., Ni Z.Y., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020; 382 (18): 1708–1720. DOI: 10.1056/NEJMoa2002032.
25. Li J., He X., Yuanyuan et al. Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Am. J. Infect. Control. [Preprint. Posted: 2020, Jun. 12]. DOI: 10.1016/j.ajic.2020.06.008.
26. Liu W., Tao Z.W., Wang L. et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin. Med. J. (Engl.). 2020; 133 (9): 1032–1038. DOI: 10.1097/CM9.0000000000000775.
27. Cen Y., Chen X., Shen Y. et al. Risk factors for disease progression in mild to moderate COVID-19 patients – a multi-center observational study. Clin. Microbiol. Infect. 2020; 26 (9): 1242–1247. DOI: 10.1016/j.cmi.2020.05.041.
28. Wang L., He W., Yu X. et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J. Infect. 2020; 80 (6): 639–645. DOI: 10.1016/j.jinf.2020.03.019.
29. Higham A., Singh D. Increased ACE2 expression in the bronchial epithelium of COPD patients who are overweight. Obesity (Silver Spring). 2020; 28 (9): 1586–1589. DOI: 10.1002/oby.22907.
30. Luo J., Rizvi H., Preeshagul I.R. et al. COVID-19 in patients with lung cancer. Ann. Oncol. 2020; 31 (10): 13861396. DOI: 10.1016/j.annonc.2020.06.007.
31. Tal-Singer R., Crapo J.D. COPD at the time of COVID-19: A COPD foundation perspective. Chronic Obstr. Pulm. Dis. 2020; 7 (2): 73–75. DOI: 10.15326/jcopdf.7.2.2020.0149.
32. Daccord C., Touilloux B., Von Garnier C. [Asthma and COPD management during the COVID-19 pandemic]. Rev. Med. Suisse. 2020; 16 (692): 933–938 (in French).
33. Meyers M.H. A case of COVID-19 infection: Chief symptom, diarrhea. Am. Fam. Physician. 2020; 101 (10): 580.
34. Dong X., Cao Y.Y., Lu X.X. et al. Eleven faces of coronavirus disease 2019. Allergy. 2020; 75 (7): 1699–1709. DOI: 10.1111/all.14289.
35. Salehi S., Abedi A., Radmard A.R. et al. Chest computed tomography manifestation of coronavirus disease 2019 (COVID-19) in patients with cardiothoracic conditions. J. Thorac. Imaging. 2020; 35 (4): W90–96. DOI: 10.1097/RTI.0000000000000531.
36. Miwa M., Nakajima M., Goto H. Peripheral “Swiss Cheese” appearance in a COVID-19 patient with chronic obstructive pulmonary disease. Am. J. Trop. Med. Hyg. 2020; 103 (2): 546. DOI: 10.4269/ajtmh.20-0605.
37. Global Initiative for Chronic Obstructive Lung Disease. GOLD COVID-19 Guidance. Available at: https://goldcopd.org/gold-covid-19-guidance/
38. Bhutani M., Hernandez P., Bourbeau J. et al. Key highlights of the Canadian Thoracic Society’s position statement on the optimization of COPD management during the COVID19 pandemic. Chest. 2020; 158 (3): 869–872. DOI: 10.1016/j.chest.2020.05.530.
39. Deslée G., Zysman M., Burgel P.R. et al. Chronic obstructive pulmonary disease and the COVID-19 pandemic: Reciprocal challenges. Respir. Med. Res. 2020; 78: 100764. DOI: 10.1016/j.resmer.2020.100764.
40. Attaway A., Hatipoğlu U. Management of patients with COPD during the COVID-19 pandemic. Cleve. Clin. J. Med. [Preprint. Posted: 2020, Jul. 17]. DOI: 10.3949/ccjm.87a.ccc007.
41. Edler C., Schröder A.S., Aepfelbacher M. et al. Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int. J. Legal. Med. 2020; 134 (4): 1275–1284. DOI: 10.1007/s00414-02002317-w.
42. Børvik T., Brækkan S.K., Enga K. et al. COPD and risk of venous thromboembolism and mortality in a general population. Eur. Respir. J. 2016; 47 (2): 473–481. DOI: 10.1183/13993003.00402-2015.
43. Latham S., Sullivan J., Williams S., Eakin M.N. Maintaining emotional well-being during the COVID-19 pandemic: A resource for your patients. Chronic Obstr. Pulm. Dis. 2020; 7 (2): 76–78. DOI: 10.15326/jcopdf.7.2.2020.0150.
44. Halpin D.M.G., Singh D., Hadfield R.M. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur. Respir. J. 2020; 55 (5): 2001009. DOI: 10.1183/13993003.01009-2020.
45. Iwabuchi K., Yoshie K., Kurakami Y. et al. [COVID-19 three cases improved with inhaled ciclesonide in the early to middle stages of pneumonia]. Available at: www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_200310.pdf (in Chinese).
46. Yang I.A., Clarke M.S., Sim E.H. et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (7): CD002991. DOI: 10.1002/14651858.CD002991.pub3.
47. Lipworth B., Chan R., Lipworth S., Rui Wen Kuo C. Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection. J. Allergy Clin. Immunol. Pract. 2020; 8 (6): 1798–1801. DOI: 10.1016/j.jaip.2020.04.014.
48. Singanayagam A., Glanville N., Cuthbertson L. et al. Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease. Sci. Transl. Med. 2019; 11 (507): eaav3879. DOI: 10.1126/scitranslmed.aav3879.
49. Tal-Singer R., Yawn B.P., Wise R. et al. The COPD foundation coronavirus disease 2019 international medical experts survey: results. Chronic Obstr. Pulm. Dis. 2020; 7 (3): 139–146. DOI: 10.15326/jcopdf.7.3.2020.0164.
50. Matsuyama S., Kawase M., Nao N. et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv [Preprint. Posted: 2020, Mar. 12]. DOI: 10.1101/2020.03.11.987016.
51. Suda K., Tsuruta M., Eom J. et al. Acute lung injury induces cardiovascular dysfunction: effects of IL-6 and budesonide/formoterol. Am. J. Respir. Cell. Mol. Biol. 2011; 45 (3): 510–516. DOI: 10.1165/rcmb.2010-0169OC.
52. Bridgewood C., Damiani G., Sharif K. et al. Rationale for evaluating PDE4 inhibition for mitigating against severe inflammation in COVID-19 pneumonia and beyond. Isr. Med. Assoc. J. 2020; 22 (6): 335–339.
53. Yen B.L., Yen M.L., Wang L.T. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19. Stem Cells Transl. Med. 2020; 9 (10): 1163–1173. DOI: 10.1002/sctm.20-0186.
Review
For citations:
Shchikota A.M., Pogonchenkova I.V., Turova E.A., Rassulova M.A., Gumenyuk S.A. Chronic obstructive pulmonary disease and COVID-19: topical issues. PULMONOLOGIYA. 2020;30(5):599-608. https://doi.org/10.18093/0869-0189-2020-30-5-599-608
Views:
8396
Email this article 